| 摘要 |
FIELD: medicine.SUBSTANCE: invention represents method of predicting efficiency of combined therapy of CHC in children, which includes analysis of absolute quantity of neutrophils of blood, characterized by the fact that before starting therapy initial level of absolute quantity of neutrophils is determined, with level 2000-3400/mcl is considered to be positive predictor of obtaining initial virological remission, and level, which exceeds 3500/mcl, is considered to be negative predictor of obtaining remission; in dynamics after 12 and 24 weeks from the start of combined therapy level of absolute quantity of neutrophils is determined, and if level of neutrophils ?1400/mcl, conclusion about positive prediction of therapy efficiency is made, and if level of absolute number of neutrophils ?2500/mcl, achievement of initial virological remission is unlikely.EFFECT: application of invention makes it possible to predict efficiency of combined therapy of CHC with pegylated IFN?-2b and ribavirin in children and makes it possible to avoid durative irrational treatment, prevent development of complications.2 dwg, 2 tbl, 3 ex |
